Elotuzumab as a novel anti-myeloma immunotherapy
Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymph...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2017-08-01
|
| Colecção: | Human Vaccines & Immunotherapeutics |
| Assuntos: | |
| Acesso em linha: | http://dx.doi.org/10.1080/21645515.2017.1327487 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|